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Abstract
Background The pharmacokinetics and tolerability of
semaglutide, a once-weekly human glucagon-like peptide-1
analog in development for the treatment of type 2 diabetes
mellitus, were investigated in subjects with/without renal
impairment (RI).
Methods Fifty-six subjects, categorized into renal function
groups [normal, mild, moderate, severe, and end-stage
renal disease (ESRD)], received a single subcutaneous dose
of semaglutide 0.5 mg. Semaglutide plasma concentrations
were assessed B480 h post-dose; the primary endpoint was
the area under the plasma concentration–time curve from
time zero to infinity.
Results Semaglutide exposure in subjects with mild/mod-
erate RI and ESRD was similar to that in subjects with
normal renal function. In subjects with severe RI, the mean
exposure of semaglutide was 22% higher than in subjects
with normal renal function, and the 95% confidence
interval (1.02–1.47) for the ratio exceeded the pre-specified
limits (0.70–1.43). When adjusted for differences in sex,
age, and body weight between the groups, all comparisons
were within the pre-specified clinically relevant limits.
Across RI groups there was no relationship between
creatinine clearance (CLCR) and semaglutide exposure, or
between CLCR and semaglutide maximum plasma drug
concentration (Cmax). Hemodialysis did not appear to affect
the pharmacokinetics of semaglutide. No appreciable
changes in safety parameters or vital signs and no serious
adverse events were noted. One subject with severe RI
reported two major hypoglycemic events.
Conclusion When adjusted for differences in sex, age, and
body weight, semaglutide exposure was similar between
subjects with RI and subjects with normal renal function.
Semaglutide (0.5 mg) was well-tolerated. Dose adjustment
may not be warranted for subjects with RI.
ClinicalTrials.gov identifier NCT00833716.
Key Points
Semaglutide exposure was similar between subjects
with mild/moderate renal impairment (RI) or end-
stage renal disease and subjects with normal renal
function; equivalence was not demonstrated in
subjects with severe RI, in whom mean exposure was
22% higher. However, when exposures were
adjusted for differences in age, sex, and body weight,
all comparisons were within the pre-specified ‘no
effect’ limits.
A single subcutaneous dose of semaglutide 0.5 mg
was well-tolerated across all renal function groups.
Semaglutide appears to be a useful treatment for
subjects with diabetes mellitus regardless of renal
status, and may not require dose adjustment.
& Thomas C. Marbury
tmarbury@ocrc.net
1 Orlando Clinical Research Center, 5055 South Orange
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Impaired renal function is a common complication of type
2 diabetes mellitus [1–3]. The prevalence of chronic renal
disease, characterized by albuminuria or impaired renal
function, is reported to be[30% among adults with type 2
diabetes, and duration of diabetes is associated with pro-
gression of renal disease [3–8]. Appropriate control of
blood glucose is known to slow down the progress of renal
impairment (RI) in patients with type 2 diabetes and kidney
dysfunction [9, 10].
The metabolism and excretion of antidiabetic drugs
required for good glycemic control may, however, be
influenced by concomitant RI [10]. Reduced renal clear-
ance, increased elimination half-life (t), and high maxi-
mum plasma drug concentration (Cmax) values of
antidiabetic drugs may lead to high and prolonged drug
exposure [11–17]. For some antidiabetic drugs, this
increases the risk of hypoglycemia, meaning that they are
unsuitable for use in patients with RI or that caution is
advised [11–17]. Therapeutic options in this particular
patient group are therefore limited.
Semaglutide (Novo Nordisk A/S, Denmark) is a human
glucagon-like peptide-1 (GLP-1) analog in phase III clin-
ical development for the treatment of type 2 diabetes [18].
Although native human GLP-1 increases insulin secretion
and decreases glucagon secretion in a glucose-dependent
manner, its short t makes it unsuitable for clinical use in
type 2 diabetes [19, 20]. Furthermore, as GLP-1 is cleared
primarily via the kidney, it may be particularly unsuit-
able for use in patients with RI [19, 20]. While semaglutide
has 94% structural homology to native human GLP-1,
modifications have been made to extend its t to approx-
imately 1 week in humans, allowing once-weekly admin-
istration [18, 21]. These modifications include acylation of
the peptide backbone with a spacer and a C-18 fatty di-acid
chain to lysine at position 26, which mediates strong
binding to albumin and potentially results in reduced renal
clearance, and an amino-acid substitution in position 8,
which results in reduced susceptibility to dipeptidyl pep-
tidase-4 (DPP-4) degradation. Studies show limited renal
excretion of semaglutide in its intact form [22]. Semaglu-
tide monotherapy has been shown to significantly improve
glycemic control and reduce body weight, with a low risk
of hypoglycemia in subjects with type 2 diabetes
[18, 21, 23].
Several studies have assessed the effect of RI on the
pharmacokinetics of GLP-1 receptor agonists
[11, 12, 24–28]. Pharmacokinetic, efficacy, and safety data
indicate that liraglutide and albiglutide have favorable
benefit–risk profiles in patients with type 2 diabetes who
also have mild or moderate RI [24, 25, 29]. Both
medications have been reported to show little or no change
in pharmacokinetics and pharmacodynamics in patients
with RI versus those with normal renal function, are well-
tolerated, and exhibit a low risk of hypoglycemia, irre-
spective of renal function [24, 25, 29, 30]. Patients with
concomitant type 2 diabetes and RI are expected to be able
to use standard treatment regimens without the need for
dose adjustments [24, 25, 30].
The aim of this study was to compare the pharmacoki-
netics of semaglutide in subjects with different degrees of
RI versus those with normal renal function, to determine
whether semaglutide dose adjustment may be required. The




Study participants were of both sexes, 18–75 years of age,
with a body mass index of B40 kg/m2. At screening,
subjects had normal renal function or RI according to
predefined creatinine clearance (CLCR) criteria using the
Cockcroft–Gault formula [31]. Subjects were classified as
one of five groups: normal renal function (CLCR[ 80 mL/
min); mild RI (CLCR[ 50 and B80 mL/min), moderate RI
(CLCR[ 30 and B50 mL/min), severe RI (CLCR
B 30 mL/min), or subjects with end-stage renal disease
(ESRD) requiring hemodialysis. Subjects with type 2 dia-
betes were allowed to participate in this study.
Renal transplant patients were excluded, as were those
with serious cardiac disease [New York Heart Association
(NYHA) heart failure functional class III or IV; myocardial
infarction within 3 months; unstable angina pectoris],
uncontrolled hypertension (diastolic blood pressure
C100 mmHg or systolic blood pressure C180 mmHg),
severe hepatic disease within the previous 12 months, and
those with elevated liver enzymes (C2.5 times upper nor-
mal range). Medications known to alter tubular secretion of
creatinine were not permitted within either 14 days or five
half-lives, whichever was longer, prior to dosing.
2.2 Treatment
Semaglutide was administered by subcutaneous injection
in the thigh (NordiPen, Novo Nordisk A/S, Denmark) as
a single 0.5 mg dose. In the ESRD group, semaglutide was
administered 1–24 h after hemodialysis, with no
hemodialysis for 48 h post-dose.
Initially, a single dose of 10 lg/kg (absolute dose range
0.7–1.2 mg) was administered to six subjects (three with
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severe RI and three with ESRD) but, based on the fre-
quency and severity of gastrointestinal adverse effects, the
10 lg/kg dose was not considered a tolerable starting dose.
Two of these six subjects experienced three serious adverse
events (AEs) (angioedema, increased hypertension, and
aggravated sciatica pain), three experienced minor or
symptoms-only hypoglycemia, and five experienced sig-
nificant nausea and/or vomiting. To improve tolerability,
the study was re-started with a lower, fixed single dose of
semaglutide 0.5 mg.
2.3 Study Design and Pharmacokinetic Sampling
This was a multicenter, single-dose, open-label, parallel-
group study (ClinicalTrials.gov identifier NCT00833716)
conducted in accordance with Good Clinical Practice [32],
the Declaration of Helsinki, and relevant guidelines for
studies in patients with RI [33, 34]. A sample size of 54
subjects (14 normal renal function and ten in each of the
four RI groups) was calculated to be sufficient for the
primary objective of the study, with a power of 82% to
show equivalence of exposure between subjects with sev-
ere RI and subjects with normal renal function. All par-
ticipants provided written consent prior to initiation of any
study-related activities. Participants were informed of the
risks and benefits of the study and were permitted to
withdraw at any time.
The study period was from Day 1 (dosing) to Day 21
(follow-up visit). Participants remained in-house for a
minimum of 72 h after dosing (Fig. 1).
To determine the plasma concentrations of semaglutide,
blood samples were taken 15 min prior to administration of
semaglutide and 2, 8, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34,
38, 42, 48, 54, 60, 66, 72, 96, 144, 192, 240, 360, and 480 h
after administration of semaglutide. For ESRD subjects on
hemodialysis, hourly blood samples (some of which were in
addition to those mentioned above) were drawn during each
of the first two hemodialysis sessions post-administration
(each hemodialysis session lasted for *2–4 h).
2.4 Assay Methodology
Semaglutide serum concentrations were measured by liquid
chromatography with tandem mass spectrometry (Celerion
Inc., Fehraltorf, Switzerland), as described elsewhere [21].
The assay measured the total plasma concentration of
semaglutide (protein bound and unbound). The lower limit
of quantification for semaglutide was 1.94 nmol/L. Blood
samples for estimation of protein binding were collected
30 min before dosing. Semaglutide binding was determined
using surface plasmon resonance biosensor technology
(Biacore T100 Instrument, GE Healthcare Bio-Sciences AB,
Umea˚, Sweden), in which semaglutide was immobilized at
the surface and diluted plasma, collected prior to dosing,
was passed over the sensor chip. Binding was determined as
the resultant change in the resonance angle of polarized
light. The affinity (kd) and fraction unbound were deter-
mined using the 1:1 binding model.
2.5 Pharmacokinetic, Safety, and Statistical
Analyses
Summary statistics and statistical analyses were based on
all subjects exposed to a 0.5 mg dose of semaglutide. The
six subjects who received a 10 lg/kg dose were evaluated
for safety (reported AEs are described in Sect. 2.2), but
were not included in the pharmacokinetics analysis set.
The primary pharmacokinetic endpoint was the area
under the semaglutide plasma concentration–time curve
(AUC) from time zero to infinity (AUC?). Secondary
pharmacokinetic endpoints included Cmax, time to reach
Cmax following drug administration (tmax), t, and apparent
total clearance of the drug from plasma after subcutaneous
administration (CL/F). In addition, for subjects in the
ESRD and normal renal function groups, AUC from time
zero to 48 h (AUC48) and AUC from 48 to 96 h
(AUC48–96) were calculated.
The terminal elimination rate constant (kz) was
approximated by log-linear regression on the log-linear
phase of the plasma concentration profile. AUC was cal-
culated using the trapezoidal rule, and AUC? was then
extrapolated from the time of last quantifiable observation
(t) to infinite time using AUC(t–?) = C(t)/kz. The t was
defined as ln2/kz and CL/F was estimated as dose/AUC?.
To assess the effect of RI on semaglutide pharmacokinetic
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Fig. 1 Study design. In the ESRD group, semaglutide was given
1–24 h after hemodialysis, with no hemodialysis for 48 h post-dose.
ESRD end-stage renal disease, Max maximum, SC subcutaneous
PK and tolerability of semaglutide in subjects with or without renal impairment
an analysis of covariance (ANCOVA) model, with renal
group as a fixed effect. In addition, because of differences in
baseline characteristics between the groups, the analysis was
performed post hoc with age, sex, and log(weight) as
explanatory variables. A two-stage procedure was pre-speci-
fied: in Stage 1 exposure was considered equivalent between
the severe RI group and the normal renal function group if the
95% confidence intervals (CIs) for the ratio of AUC?
(unadjusted) were contained within the pre-specified ‘no
effect’ interval of 0.70–1.43 (both inclusive). The ‘no effect’
boundaries were selected based on the observation that
semaglutide, as a GLP-1 analog, displays a wide therapeutic
index. If equivalence was not shown in Stage 1, only then
was Stage 2 performed, where equivalence between the mild
RI group and the normal renal function group, and between
the moderate RI group and the normal renal function group,
was tested. Data from the ESRD group were also analyzed
regardless of Stage 1 outcome. Correction for multiplicity due
to multiple testing was performed by using a CI at the 95%
level for each stage instead of 90% and a hierarchical testing
scheme for the comparisons in Stage 2 (mild vs. normal
followed by moderate vs. normal). As Stage 2 was per-
formed, further analysis of the association between CLCR and
AUC? and CLCR and Cmax was carried out (as pre-specified)
by linear regression of the log-transformed endpoint, with
log-transformed CLCR as the independent variable. Cmax was
analyzed in the same model as AUC?.
Tolerability of semaglutide was assessed through AEs,
physical examination, electrocardiogram, vital signs,
hypoglycemic events, plasma glucose, and clinical labo-
ratory parameters (biochemistry, hematology, and urinal-
ysis). Treatment-emergent AEs (TEAEs) were defined as
events occurring between the dosing day and the follow-up
visit ?14 days (i.e., up to 5 weeks post-dose, correspond-
ing to five half-lives of semaglutide), or starting before the
dosing day with increasing severity during the period.
Hypoglycemic episodes were defined as ‘major’, ‘mi-
nor’, or ‘symptoms only’: major if the subject was unable
to self-treat, minor if the subject was able to self-treat and
plasma glucose was \3.1 mmol/L (56 mg/dL), or symp-
toms only if the subject was able to self-treat and had either
a plasma glucose measurement C3.1 mmol/L or no plasma
glucose measurement available. Safety endpoints were
summarized using descriptive statistics.
3 Results
3.1 Subject Demographics
Following the decision to reduce the semaglutide dose
from 10 lg/kg to 0.5 mg, a total of 56 subjects were
exposed to a single 0.5 mg dose of semaglutide;
55 subjects completed the study and one subject withdrew
due to nausea. Of those entering the study, 14 had normal
renal function, 11 had mild RI, 11 had moderate RI, ten had
severe RI, and ten had ESRD requiring hemodialysis. The
enrollment of subjects with normal renal function was
aimed to be balanced with regard to overall age, sex, and
body weight distribution of the subjects with RI (Table 1).
However, subjects with normal renal function had, on
average, a lower body weight and were older than subjects
with ESRD, and had a higher body weight and were
younger than subjects with mild to severe RI. All groups
included male and female subjects but, overall, there were
more males than females. Of the subjects with RI, nine had
type 2 diabetes as a concomitant illness at baseline.
3.2 Pharmacokinetics
Mean semaglutide plasma concentration over time by renal
group is shown in Fig. 2, and all pharmacokinetic end-
points for semaglutide are shown in Table 2. Geometric
means [coefficient of variation (CV), %] for AUC?
showed no consistent trend with decreasing renal function,
ranging from a lowest exposure of 2567 nmol h/L (18%) in
the ESRD group to a highest exposure of 3179 nmol h/L
(22%) in the severe RI group. Subjects with severe RI had a
22% higher mean exposure of semaglutide than subjects
with normal renal function and the ratio did not demon-
strate equivalence according to the predefined criteria for
95% CI (0.70–1.43). The CIs for the ratios of AUC? for
semaglutide in the mild and moderate RI and ESRD groups
were within the ‘no effect’ interval and were considered
equivalent to the normal renal function group. When
adjusted for differences between groups in age, sex, and
log(weight), all of the 95% CIs for the ratio of AUC?
between each RI group and the normal renal function group
were contained within the pre-specified interval
(0.70–1.43; Table 2).
Mean Cmax for semaglutide was highest in subjects with
normal renal function (10.3 nmol/L) and lowest in subjects
with ESRD (7.4 nmol/L), whereas across the other groups
meanCmax was 9.0–9.8 nmol/L (Table 2). When adjusted for
differences between groups in age, sex, and log(weight),Cmax
was 10–20% lower in subjects with RI than in subjects with
normal renal function, with no clear trend in severity of RI
(Table 2). The tmax varied across the groups (range 24–51 h);
mean t was longer in subjects with severe RI (221 h) and
those with ESRD (243 h) than in subjects with mild and
moderate RI or normal renal function.
Exposure to semaglutide (AUC?) as a function of CLCR
and Cmax as a function of CLCR in all subjects, following a
single dose of 0.5 mg semaglutide, are shown in Fig. 3a, b,
respectively. There was no linear relationship between
CLCR across groups (normal, mild, moderate, severe, and
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ESRD) and semaglutide exposure (p = 0.127), or between
CLCR across groups and semaglutide Cmax (p = 0.164).
When adjusted for differences in age, sex, and body
weight, the small observed slopes for AUC? and Cmax
(approximately -0.06 and 0.08, respectively) were
unchanged; however, the association between CLCR and
AUC? was statistically significant (p = 0.041). A slope of
-0.06 corresponds to an increase in exposure of 14% in
subjects with a CLCR of 10 mL/min versus subjects with a
CLCR of 90 mL/min.
The point estimate of the ratio (ESRD group/normal
renal function group) for AUC48 (without hemodialysis)
was 0.72 (90% CI 0.57–0.91) and for AUC48–96 (with
hemodialysis) was 0.82 (90% CI 0.67–0.99). The estimated
ratios were also comparable when adjusted for differences
in age, sex, and body weight [0.81 (90% CI 0.66–1.01) for
AUC48 and 0.93 (90% CI 0.78–1.10) for AUC48–96], indi-
cating that hemodialysis did not appear to affect the
pharmacokinetics of semaglutide.
There was no difference in protein binding between the
groups; the fraction of unbound semaglutide across renal
groups was low (\1%; data not shown). All subjects had
normal albumin concentrations at baseline and throughout
the study (except for one subject in the normal renal
function group at the screening visit).
3.3 Adverse Events and Other Safety Assessments
The safety population comprised all 56 enrolled subjects who
received semaglutide 0.5 mg. One subject in the mild RI
group withdrew from the study on Day 2 because of nausea.
Overall TEAEs are shown in Table 3. In total, 38 subjects
experienced 89 events with semaglutide 0.5 mg; none were
serious or severe and the majority were mild. The AE profiles
in the normal renal function and mild and moderate RI groups
were similar; compared with these three groups, the propor-
tion of subjects experiencing AEs was higher in the severe RI
group and lower in the ESRD group. The most frequently
Table 1 Baseline
demographics
Parameter Renal function group
Normal Mild Moderate Severe ESRD
Subjects (n) 14 11 11 10 10
Sex [M/F (n)] 9/5 6/5 6/5 6/4 7/3
Age (years) 54.6 ± 9.1 62.9 ± 8.0 66.5 ± 6.6 62.8 ± 9.1 48.2 ± 7.2
Weight (kg) 84.9 ± 19.1 80.1 ± 13.8 78.7 ± 16.5 78.1 ± 22.7 97.2 ± 15.7
BMI (kg/m2) 29.2 ± 4.1 28.5 ± 4.3 27.9 ± 5.2 27.8 ± 5.2 31.7 ± 5.1
FPG (mmol/L) 5.6 ± 0.5 5.8 ± 0.6 6.6 ± 1.8 5.8 ± 1.6 5.2 ± 2.4
T2D (n) 0 1 2 2 4
Estimated CLCR
a (mL/min) 119.7 ± 42.6 63.2 ± 9.0 41.5 ± 5.7 21.5 ± 6.2 15.4 ± 6.2
All data are mean ± standard deviation unless stated otherwise
BMI body mass index, CLCR creatinine clearance, ESRD end-stage renal disease, F female, FPG fasting
plasma glucose, M male, T2D type 2 diabetes mellitus



































Normal Mild Moderate Severe ESRD
Fig. 2 Mean semaglutide
plasma concentration over time
by renal function group after a
single dose of semaglutide
0.5 mg. The study period was
from Day 1, 0 h (dosing) to
Day 21, 480 h (follow-up visit).
ESRD end-stage renal disease
PK and tolerability of semaglutide in subjects with or without renal impairment
reported TEAEs were gastrointestinal (a total of 35 subjects
experienced 61 events), with nausea being the most frequent
(41% of subjects). A higher proportion of subjects experi-
enced nausea in the severe group than in all other groups. For
AEs in the six subjects who received a single dose of
semaglutide 10 lg/kg, see Sect. 2.2.
One subject with severe RI (who did not have type 2
diabetes, but had experienced nausea, vomiting, and
decreased appetite from the dosing day) had two major
hypoglycemic events, one subject with moderate RI and
one with ESRD experienced minor hypoglycemia, and two
subjects in the moderate RI group experienced symptoms-
only hypoglycemia.
No clinically significant values or appreciable changes
in vital signs (blood pressure and pulse), electrocardio-
gram, physical examinations, or clinical laboratory
assessments were observed.
4 Discussion
We examined the human GLP-1 analog semaglutide in
subjects with normal renal function and those with varying
degrees of RI, to investigate whether the pharmacokinetics
change across groups and to determine whether dose
adjustments are needed. The study population included a
broad range of subjects with varying severities of RI: mild,
moderate, severe, and a group with ESRD undergoing
regular hemodialysis.
The results of this study demonstrate that, for moderate
or mild RI, or in subjects with ESRD, the exposure of
semaglutide is within the ‘no effects’ limits, compared with
the normal renal function group. The comparison between
the group with normal renal function and the group with
severe RI did not demonstrate equivalence (the 95% CI
exceeded the ‘no effect’ limits), and the mean semaglutide
exposure was 22% higher in the severe RI group. Cmax for
the ESRD group was outside the pre-specified ‘no effects’
limits and appeared to be lower than in the other RI groups.
However, baseline characteristics of subjects with normal
renal function were somewhat different from those in the
four RI groups. On average, subjects with normal renal
function had a higher body weight and were younger
(84.9 kg, 54.6 years) than subjects in the mild, moderate,
and severe RI groups (78.1–80.1 kg, 62.8–66.5 years) but
had a lower body weight and were older than subjects with
ESRD (97.2 kg, 48.2 years). When the data were adjusted
for differences in age, sex, and body weight among the
Table 2 Pharmacokinetic endpoints for a single dose of semaglutide 0.5 mga
Parameter Renal function group
Normal Mild Moderate Severe ESRD
Primary
AUC? (nmol h/L) 2600 (27) 2615 (19)
b 2999 (20)c 3179 (22) 2567 (18)b
AUC? estimated ratio (95% CI)
d 1.01 (0.83–1.21) 1.15 (0.96–1.38) 1.22 (1.02–1.47) 0.99 (0.82–1.19)
Adjusted analysise
AUC? estimated ratio (95% CI)
d 0.99 (0.85–1.16) 1.07 (0.91–1.27) 1.13 (0.97–1.32) 1.10 (0.94–1.28)
Secondary
Cmax (nmol/L) 10.3 (35) 9.8 (22)
c 9.0 (44) 9.8 (37) 7.4 (22)b
Cmax estimated ratio (90% CI)
d 0.95 (0.76–1.20) 0.88 (0.70–1.10) 0.95 (0.75–1.19) 0.72 (0.57–0.91)
Adjusted analysise
Cmax estimated ratio (90% CI)
d 0.90 (0.73–1.11) 0.79 (0.64–0.99) 0.86 (0.70–1.06) 0.82 (0.66–1.01)
tmax (h) 24 (8, 66) 35 (14, 96)
c 24 (14, 96) 41 (16, 96) 51 (28, 72)b
t (h) 183 (15) 169 (14)
b 201 (14)c 221 (26) 243 (19)b
CL/F (L/h) 0.047 (27) 0.046 (19)c 0.041 (20) 0.038 (22) 0.047 (18)b
Values are geometric means [CV (%)] for AUC?, Cmax, t, and CL/F unless stated otherwise; and median (minimum, maximum) for tmax
AUC? area under the plasma concentration–time curve from time zero to infinity, CI confidence interval, Cmax maximum plasma drug
concentration, CL/F apparent total clearance of the drug from plasma after subcutaneous administration, CV coefficient of variance, ESRD end-
stage renal disease, t elimination half-life, tmax time to reach maximum plasma drug concentration following drug administration
a The pharmacokinetic population comprised all subjects exposed to subcutaneous semaglutide 0.5 mg with an evaluable drug profile and no
relevant protocol violations
b The corresponding parameter could only be estimated for n = 9
c The corresponding parameter could only be estimated for n = 10
d The corresponding parameter could only be estimated versus the normal renal function group
e Adjustment analyses for the primary endpoint and Cmax were conducted with age, sex, and log(weight) as explanatory variables
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Slope: –0.06
Fig. 3 a Exposure of
semaglutide and b maximum
semaglutide plasma
concentration versus creatinine
clearance following a single
dose of semaglutide 0.5 mg by
renal function group. AUC?
area under the plasma
concentration–time curve from




Table 3 Treatment-emergent adverse events
System organ class and preferred term Renal function group [N (%) E]
Normal Mild Moderate Severe ESRD Total
Subject 14 11 11 10 10 56
Overall
TEAEs 10 (71) 23 7 (64) 14 8 (73) 17 9 (90) 25 4 (40) 10 38 (68) 89
Withdrawals 0 1 (9) 1 0 0 0 1 (2) 1
Severity
Mild 9 (64) 17 6 (55) 10 8 (73) 17 9 (90) 18 3 (30) 3 35 (63) 65
Moderate 3 (21) 6 2 (18) 4 0 2 (20) 7 3 (30) 7 10 (18) 24
Severe 0 0 0 0 0 0
Gastrointestinal 7 (50) 10 7 (64) 10 8 (73) 13 9 (90) 21 4 (40) 7 35 (63) 61
Nausea 4 (29) 4 4 (36) 4 4 (36) 4 9 (90) 12 2 (20) 2 23 (41) 26
Vomiting 3 (21) 3 1 (9) 1 3 (27) 3 4 (40) 6 3 (30) 5 14 (25) 18
Dyspepsia 2 (14) 2 3 (27) 4 3 (27) 3 1 (10) 10 0 9 (16) 10
A TEAE is defined as an event occurring between the dosing day and the follow-up visit ?14 days (i.e., up to 5 weeks post-dose, corresponding to five
half-lives of semaglutide), or starting before the dosing day with increasing severity during the period
E number of adverse events, ESRD end-stage renal disease, N number of subjects with adverse event, TEAE treatment-emergent adverse event, %
proportion of subjects in analysis set having adverse event
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groups, all comparisons for exposure were within the ‘no
effect’ limits, and Cmax was similar between RI and ESRD
groups, which were all 10–20% lower than the normal
renal function group (Table 2). In addition, there was no
relationship between CLCR across RI groups (normal, mild,
moderate, severe, and ESRD) and semaglutide exposure, or
between the CLCR and semaglutide Cmax. The pharma-
cokinetics of semaglutide did not appear to be affected by
hemodialysis, as the semaglutide exposure ratio of ESRD
subjects to healthy subjects during dialysis (AUC48–96) was
similar to the ratio obtained when subjects were not
receiving dialysis (AUC48).
Semaglutide (single dose of 0.5 mg) was well-tolerated,
despite not being administered with a dose-escalation regi-
men. As expected, the AEs were mainly gastrointestinal and,
while one subject withdrew from the study because of nausea,
the majority of events were mild, and all were mild to
moderate, in severity. While this was a single-dose study, the
semaglutide dose-escalation regimens used in two other
studies—Kapitza et al. [21] (starting dose 0.25 mg for
4 weeks, then 0.5 mg for 4 weeks and 1.0 mg for 5 weeks)
and Nauck et al. [18] (0.4 mg for 1 week followed by 0.8 mg
for 11 weeks)—reduced the incidence of nausea, indicating
tolerance development compared with no or weekly dose
escalation. The starting dose and dose-escalation regimen
reported by Kapitza et al. [21] has been used in the
semaglutide phase III development program, in which
semaglutide showed a gastrointestinal AE profile comparable
to that of other GLP-1 receptor agonists [23]. As the Cmax in
the RI groups was not higher than in the normal renal function
group—indeed, when adjusted for age, sex and body weight,
Cmax was 10–20% lower than in the normal group—no tol-
erability issues are expected in clinical practice.
In this study, two major episodes of hypoglycemia were
reported in a subject with severe RI (who did not have
type 2 diabetes). This may be treatment related or could be
linked to the presence of RI; in a retrospective cohort
analysis of 243,222 patients, Moen et al. [14] showed that
chronic renal disease is a significant risk factor for hypo-
glycemia in patients with or without diabetes. No other
safety or tolerability concerns were raised with a single
dose of semaglutide 0.5 mg, and none of the TEAEs were
classified as serious or severe.
This study was conducted according to regulatory
standards comprising four RI groups (mild, moderate and
severe RI, and ESRD), with C10 subjects in each group
and a comparable reference group with normal renal
function [33, 34]; the results indicate that the pharma-
cokinetic properties of semaglutide are not significantly
affected by renal function. Therefore, specific dose
adjustment may not be warranted in subjects with RI. Our
study is supported by a recent trial reporting the absorption,
metabolism, and excretion of a single subcutaneous 0.5 mg
dose of [3H]-radiolabeled semaglutide in healthy male
subjects, showing that semaglutide has very limited renal
excretion in its intact form [22].
Other available GLP-1 receptor agonists have been
approved for use in mild and moderate RI [35–40]. These
drugs are not recommended for patients with severe RI,
ESRD, or who are on dialysis because of limited thera-
peutic experience [30, 35]. Subjects with a broad variety of
RI were enrolled in the Semaglutide Unabated Sustain-
ability in Treatment of Type 2 Diabetes (SUSTAIN) pro-
gram (the phase III development program for semaglutide).
Recently, findings from the SUSTAIN 6 (Trial to
Evaluate Cardiovascular and Other Long-term Outcomes
with Semaglutide in Subjects with Type 2 Diabetes) car-
diovascular outcomes study—in which more than two-
thirds of patients had some degree of RI (estimated
glomerular filtration rate \90 mL/min/1.73 m2)—showed
that treatment with semaglutide (on a background of
standard of care) resulted in significant and sustained
reductions in glycated hemoglobin (HbA1c) versus placebo
(mean HbA1c was 0.7 and 1.0 percentage points lower with
semaglutide 0.5 and 1.0 mg, respectively, vs. placebo, both
p\ 0.001). In the SUSTAIN 6 study, gastrointestinal AEs
were more frequent with semaglutide than with placebo,
but most were mild or moderate in severity [23]. In a
subgroup analysis for the primary outcome (first occur-
rence of cardiovascular death, non-fatal myocardial
infarction, or non-fatal stroke), no significant treatment
interactions were identified for the renal function sub-
groups analyzed [23]. Therefore, SUSTAIN 6 showed that
the effects of semaglutide on the primary composite end-
point were not affected by renal subgroup [23].
5 Conclusion
When adjusted for differences in sex, age, and body
weight, semaglutide exposure is not affected by RI.
Therefore, semaglutide appears to be a useful treatment
option for patients with type 2 diabetes who also have
impaired renal function, including those with ESRD
undergoing hemodialysis. Dose adjustment may not be
warranted for patients with RI.
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